The impact of tralokinumab on quality of life and school in patients aged 12-17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial. (2023). SKIN The Journal of Cutaneous Medicine, 7(2), s139. https://doi.org/10.25251/skin.7.supp.139